Several activities have been underway since the last IHGC meeting in Spain. As reported during that meeting, the German Hop Growers Association has formally joined the US Hop Industry in providing funds and coordination for international MRL harmonization efforts. This collaboration provides funding for Matthew Lantz and his team at Bryant Christie Inc. (BCI) to work on an expanded list of MRL priorities and related issues in key export markets. The joint effort is coordinated by Otmar Weingarten, Reinhold Kugel, Ann George, and Matt Lantz.

Weingarten, Kugel and Lantz attended the meeting of the EU Commodity Expert Group for Hops during 22-24 October in Slovenia. During this meeting CEG members were briefed on current program priorities, including the EU Cut-Off Criteria and Korea transition to a positive list system for MRL enforcement.

**EU Cut-Off Criteria:** BCI has generated an assessment of what priority chemicals for the hop industry might be subject to EU cut-off criteria moving ahead (meaning they could be in jeopardy of being eliminated). The preliminary list was distributed at the recent CEG meeting and is attached. Additional compounds will be added as they are identified and reviews are scheduled. This chart will guide our future work in the EU. For compounds that are just starting reviews and have initial indications of potential problems, we will contact and work with registrants. When the European Commission SCoPAFF Committee is meeting, we can ask CEG members to contact member state representatives on the committee to provide comments. BCI will notify the hop industry well in advance of when cut-off dates occur.

**Korea transition to a positive list system:** During the next two months BCI will continue to assess the status of hop MRLs that need to be established during the next three years, as Korea transitions to their new regulatory system. Korea recently established a large number of provisional MRLs for hops, providing additional time for permanent MRLs to be evaluated:

- **Korea (provisional MRLs)**
  - 2,4-D: New MRL proposed at 0.08 ppm. U.S. MRL is 0.2 ppm.
  - Abamectin: MRL proposed at 0.15 ppm; same as current Codex deferral. U.S. MRL is 0.15 ppm.
  - Cyazofamid: MRL proposed at 0.1 ppm; currently 15 ppm Codex deferral. U.S. MRL is 10 ppm.
  - Bifenazate: MRL proposed at 20 ppm; same as current Codex deferral. U.S. MRL is 15 ppm.
  - Bifenthrin: MRL proposed at 20 ppm; same as current Codex deferral. U.S. MRL is 10 ppm.
  - Carfentrazone-ethyl: New MRL proposed at 0.1 ppm. U.S. MRL is 0.1 ppm.
  - Cloethodim: New MRL proposed at 0.05 ppm. U.S. MRL is 0.5 ppm.
  - Clopyralid: New MRL proposed at 3 ppm. U.S. MRL is 5 ppm.
  - Cyflufenamid: New MRL proposed at 0.1 ppm. U.S. MRL is 5 ppm.
  - Dimethenamid-P: New MRL proposed at 0.05 ppm. U.S. MRL is 0.05 ppm.
  - Diquat dibromide: New MRL proposed at 0.02 ppm. U.S. MRL is 0.2 ppm.
  - Dithianon: MRL proposed at 300 ppm; same as current Codex deferral. U.S. MRL is 100 ppm (import tolerance).
  - Ethoprop: New MRL proposed at 0.02 ppm. U.S. MRL is 0.02 ppm.
  - Etoxazole: MRL proposed at 15 ppm; same as current Codex deferral. U.S. MRL is 7 ppm.
  - Famoxadone: New MRL proposed at 0.05 ppm. U.S. MRL is 80 ppm.
  - Fenazaquin: MRL proposed at 30 ppm; same as current Codex deferral. U.S. MRL is 30 ppm.
  - Fenpyroximate: MRL proposed at 15 ppm; same as current Codex deferral. U.S. MRL is 10 ppm.
  - Flonicamid: MRL proposed at 20 ppm; same as current Codex deferral. U.S. MRL is 20 ppm.
  - Flumioxazin: New MRL proposed at 0.1 ppm. U.S. MRL is 0.05 ppm.
Fluopicolide: New MRL proposed at 0.1 ppm. U.S. MRL is 15 ppm.
Flutriafol: New MRL proposed at 0.3 ppm. U.S. MRL is 20 ppm.
Folpet: New MRL proposed at 0.5 ppm. U.S. MRL is 120 ppm.
Fosetyl-Al: MRL proposed at 0.05 ppm; currently 1500 ppm Codex deferral. U.S. MRL is 45 ppm.
Glufosinate-ammonium: New MRL proposed at 0.05 ppm. There is no U.S. MRL.
Glyphosate: New MRL proposed at 0.05 ppm. U.S. MRL is 7 ppm.
Hexythiazox: MRL proposed at 3 ppm; same as current Codex deferral. U.S. MRL is 20 ppm.
Mancozeb: MRL proposed at 0.05 ppm; currently 30 ppm Codex deferral. There is no U.S. MRL.
Metaldehyde: New MRL proposed at 0.05 ppm. U.S. MRL is 0.1 (regional tolerance).
Metiram: MRL proposed at 0.05 ppm; currently 30 ppm Codex deferral. There is no U.S. MRL.
Metrafenone: MRL proposed at 70 ppm; same as current Codex deferral. U.S. MRL is 70 ppm.
Naled: New MRL proposed at 0.5 ppm. U.S. MRL is 0.5 ppm.
Norflurazon: New MRL proposed at 0.05 ppm. U.S. MRL is 3 ppm.
Pendimethalin: MRL proposed at 0.05 ppm; same as current Codex deferral. U.S. MRL is 0.1 ppm.
Pymetrozine: New MRL proposed 0.03 ppm. U.S. MRL is 6 ppm.
Quinoxyfen: MRL proposed at 1 ppm; same as current Codex deferral. U.S. MRL is 1 ppm.
Spinetoram: New MRL proposed at 0.05 ppm. U.S. MRL is 22 ppm.
Spinosad: New MRL proposed at 0.05 ppm. U.S. MRL is 22 ppm.
Tebuconazole: MRL proposed at 40 ppm; same as current Codex deferral. U.S. MRL is 35 ppm.
Triflumizole: MRL proposed at 30 ppm; same as current Codex deferral. U.S. MRL is 50 ppm.

**Note: These are proposed provisional MRLs without a domestic registered use in Korea. If/when established, these MRLs will be deleted after implementation of the positive list system (PLS) unless import tolerances are applied for and established before January 1, 2022.

**MRL Tracking Chart:** This document is being updated to include European trade names, along with those used in the US.

Submitted by: Ann E. George, Hop Growers of America